Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10365 in RET Fusion-Positive NSCLC
NCT06147570Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Sep 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hs-10365 in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Objective Response Rate up to 48 months. Started Sep 2023; status: recruiting.
02
Drugs
hs-10365
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06147570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147570.